Valuation: Neuland Laboratories Limited

Market Cap 245B 2.57B 2.3B 2.13B 1.93B 3.61B 3.67B 25.61B 10.13B 128B 9.65B 9.45B 405B P/E 2027 *
51.2x
P/E 2028 * 39.2x
Enterprise Value 247B 2.6B 2.33B 2.15B 1.95B 3.65B 3.71B 25.89B 10.24B 129B 9.76B 9.55B 410B EV / Sales 2027 *
10.2x
EV / Sales 2028 * 8.48x
Free-Float
62.26%
Yield 2027 *
0.12%
Yield 2028 * 0.16%
1 day+0.79%
1 week-0.78%
Current month-10.84%
1 month-12.92%
3 months+2.71%
6 months+32.38%
Current year+25.57%
1 week 18,123.75
Extreme 18123.75
19,351.75
1 month 18,123.75
Extreme 18123.75
22,149.9
Current year 11,500
Extreme 11500
24,235.05
1 year 11,500
Extreme 11500
24,235.05
3 years 3,775
Extreme 3775
24,235.05
5 years 965.85
Extreme 965.85
24,235.05
10 years 247.3
Extreme 247.3
24,235.05
Manager TitleAgeSince
Chief Executive Officer 47 2026-03-31
Director of Finance/CFO - 2022-11-22
Chief Tech/Sci/R&D Officer - 2023-02-28
Director TitleAgeSince
Director/Board Member 50 2001-12-31
Chairman 82 1984-01-06
Director/Board Member 47 2007-02-28
Change 5-day change 1-year change 3-year change Capi.($)
+0.79%-0.78%+18.90%+412.37% 2.56B
+0.45%+3.13%+54.96%+125.16% 1,135B
+0.94%+4.93%+39.86%+78.72% 635B
+0.39%+1.44%+25.77%+97.48% 505B
+1.43%+4.31%+46.20%+67.12% 378B
-3.21%-2.10%+60.72%+33.22% 358B
-0.41%+2.64%+22.48%+49.82% 295B
+0.23%+3.66%+2.57%+23.69% 266B
+1.22%+4.63%+52.40%+64.85% 237B
+1.70%+3.67%+31.21%+102.15% 193B
Average +0.32%+2.12%+35.51%+105.46% 400.62B
Weighted average by Cap. +0.42%+2.84%+41.39%+83.82%

Financials

2027 *2028 *
Net sales 24.18B 254M 227M 210M 190M 356M 362M 2.53B 1B 12.65B 954M 933M 40.04B 29.06B 305M 273M 253M 229M 428M 435M 3.04B 1.2B 15.2B 1.15B 1.12B 48.12B
Net income 4.8B 50.43M 45.1M 41.72M 37.78M 70.71M 71.86M 502M 199M 2.51B 189M 185M 7.95B 6.26B 65.85M 58.88M 54.47M 49.32M 92.31M 93.82M 656M 259M 3.28B 247M 242M 10.37B
Net Debt 2.69B 28.27M 25.28M 23.39M 21.18M 39.63M 40.28M 281M 111M 1.41B 106M 104M 4.45B 1.58B 16.59M 14.83M 13.72M 12.42M 23.25M 23.63M 165M 65.31M 825M 62.25M 60.92M 2.61B
Projected Income Statement - Annual - Neuland Laboratories Limited
Logo Neuland Laboratories Limited
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Employees
2,183
Date Price Change Volume
26-10-26 ₹19,074.60 +0.79% 2,054
26-10-23 ₹18,924.25 -0.01% 5,485
26-10-22 ₹18,926.95 -0.24% 1,115
26-10-21 ₹18,972.35 -1.31% 4,520
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Neuland Laboratories Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
19,074.60INR
Average target price
24,678.50INR
Spread / Average Target
+29.38%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Neuland Laboratories Limited
  1. Stock Market
  2. Stocks
  3. 524558 Stock